Neuren Pharmaceuticals Limited (NURPF) Stock Forecast & Price Target

Compare

55 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NURPF Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Neuren

Pharmaceuticals Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NURPF Stock 12 Month Forecast

Average Price Target

$17.27

▲(57.43% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Neuren Pharmaceuticals Limited in the last 3 months. The average price target is $17.27 with a high forecast of $20.43 and a low forecast of $12.09. The average price target represents a 57.43% change from the last price of $10.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20.434323,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.085164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,11.725717153846153,12.451434307692308,13.177151461538461,13.902868615384616,14.628585769230769,15.354302923076922,16.080020076923077,16.805737230769232,17.531454384615383,18.257171538461538,18.98288869230769,19.708605846153844,{"y":20.434323,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,11.482307692307693,11.964615384615385,12.446923076923078,12.929230769230768,13.411538461538461,13.893846153846154,14.376153846153846,14.858461538461539,15.34076923076923,15.823076923076922,16.305384615384614,16.787692307692307,{"y":17.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,11.083474153846154,11.166948307692309,11.250422461538461,11.333896615384615,11.41737076923077,11.500844923076924,11.584319076923077,11.667793230769231,11.751267384615385,11.83474153846154,11.918215692307692,12.001689846153846,{"y":12.085164,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.46,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.43

Average Price Target$17.27

Lowest Price Target$12.09

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Wakim

Bell Potter

$12.95→$14.24

Buy

29.81%

Upside

Reiterated

08/12/25

Bell Potter Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$20

Buy

82.33%

Upside

Reiterated

08/08/25

Ord Minnett Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

Elyse Shapiro

Canaccord Genuity

$18.2

Buy

65.92%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Neuren Pharmaceuticals Limited (NURPF), Zymeworks (ZYME)

Tanushree Jain

Petra Capital

$20.36

Buy

85.57%

Upside

Reiterated

08/06/25

Petra Capital Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

David Stanton

Jefferies

$18.06→$18.38

Buy

67.58%

Upside

Reiterated

07/18/25

Jefferies Keeps Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

Rachael Harwood

Macquarie

$12.04

Buy

9.75%

Upside

Reiterated

06/18/25

Melissa Benson

Wilsons

$17.15

Buy

56.37%

Upside

Reiterated

02/28/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Wakim

Bell Potter

$12.95→$14.24

Buy

29.81%

Upside

Reiterated

08/12/25

Bell Potter Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$20

Buy

82.33%

Upside

Reiterated

08/08/25

Ord Minnett Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)

Elyse Shapiro

Canaccord Genuity

$18.2

Buy

65.92%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Neuren Pharmaceuticals Limited (NURPF), Zymeworks (ZYME)

Tanushree Jain

Petra Capital

$20.36

Buy

85.57%

Upside

Reiterated

08/06/25

Petra Capital Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

David Stanton

Jefferies

$18.06→$18.38

Buy

67.58%

Upside

Reiterated

07/18/25

Jefferies Keeps Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

Rachael Harwood

Macquarie

$12.04

Buy

9.75%

Upside

Reiterated

06/18/25

Melissa Benson

Wilsons

$17.15

Buy

56.37%

Upside

Reiterated

02/28/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neuren Pharmaceuticals Limited

1 Month

xxx

Success Rate

5/7 ratings generated profit

Average Return

+2.44%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +2.44% per trade.

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+11.23%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +11.23% per trade.

1 Year

Tanushree JainPetra Capital

Success Rate

5/7 ratings generated profit

Average Return

+34.34%

reiterated a buy rating 22 days ago

Copying Tanushree Jain's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +34.34% per trade.

2 Years

xxx

Success Rate

5/7 ratings generated profit

Average Return

+133.33%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +133.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NURPF Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NURPF has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NURPF average Analyst price target in the past 3 months is 17.27.

Each month's total comprises the sum of three months' worth of ratings.

NURPF Financial Forecast

NURPF Earnings Forecast

Next quarter’s earnings estimate for NURPF is $0.19 with a range of $0.13 to $0.26. The previous quarter’s EPS was $0.08. NURPF beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.10% of the time in the same period. In the last calendar year NURPF has Outperformed its overall industry.

NURPF Sales Forecast

Next quarter’s sales forecast for NURPF is $34.83M with a range of $21.05M to $59.66M. The previous quarter’s sales results were $18.37M. NURPF beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year NURPF has Outperformed its overall industry.

NURPF Stock Forecast FAQ

What is NURPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Neuren Pharmaceuticals Limited’s 12-month average price target is 17.27.

What is NURPF’s upside potential, based on the analysts’ average price target?

Neuren Pharmaceuticals Limited has 57.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NURPF a Buy, Sell or Hold?

Neuren Pharmaceuticals Limited has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Neuren Pharmaceuticals Limited’s price target?

The average price target for Neuren Pharmaceuticals Limited is 17.27. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.43 ,the lowest forecast is $12.09. The average price target represents 57.43% Increase from the current price of $10.97.

What do analysts say about Neuren Pharmaceuticals Limited?

Neuren Pharmaceuticals Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of NURPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neuren Pharmaceuticals Limited (NURPF) Stock Forecast & Price Target

NURPF Analyst Ratings

NURPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neuren Pharmaceuticals Limited

NURPF Analyst Recommendation Trends

NURPF Financial Forecast

NURPF Earnings Forecast

NURPF Sales Forecast

NURPF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts